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OBJECTIVE—Type 1 diabetes can be inhibited in standard NOD
mice by autoantigen-speciﬁc immunotherapy targeting patho-
genic CD8+ T-cells. NOD.b2m
null.HHD mice expressing human
HLA-A2.1 but lacking murine major histocompatibility complex
class I molecules develop diabetes characterized by CD8 T-cells
recognizing certain autoantigenic peptides also targeted in hu-
man patients. These include peptides derived from the pancreatic
b-cell proteins insulin (INS1/2 A2–10 and INS1 B5–14) and islet-
speciﬁc glucose-6-phosphatase catalytic subunit–related protein
(IGRP265–273 and IGRP228–236). Hence, NOD.b2m
null.HHD mice
represent a model system for developing potentially clinically
translatable interventions for suppressing diabetogenic HLA-
A2.1–restricted T-cell responses.
RESEARCH DESIGN AND METHODS—Starting at 4–6 weeks
of age, NOD.b2m
null.HHD female mice were injected intrave-
nously with syngeneic splenocytes to which various admixtures
of the four above-mentioned peptides were bound by the cross-
linking agent ethylene carbodiimide (ECDI).
RESULTS—Treatment with such cells bearing the complete
cocktail of INS and IGRP epitopes (designated INS/IGRP-SPs)
signiﬁcantly inhibited diabetes development in NOD.b2m
null.
HHD recipients compared with controls receiving splenocytes
coupled with an irrelevant HLA-A2.1–restricted Flu16 peptide.
Subsequent analyses found syngeneic splenocytes bearing the
combination of the two ECDI-coupled IGRPs but not INS pep-
tides (IGRP-SPs or INS-SPs) effectively inhibited diabetes devel-
opment in NOD.b2m
null.HHD mice. This result was supported by
enzyme-linked immunospot (ELISPOT) analyses indicating com-
bined INS/IGRP-SPs diminished HLA-A2.1–restricted IGRP but
not INS autoreactive CD8+ T-cell responses in NOD.b2m
null.
HHD mice.
CONCLUSIONS—These data support the potential of a cell
therapy approach targeting HLA-A2.1–restricted IGRP autoreac-
tive CD8 T-cells as a diabetes intervention approach in appropri-
ate human patients. Diabetes 60:1229–1236, 2011
I
t has been long recognized that in both humans and
NOD mice the autoimmune destruction of insulin-
producing pancreatic b-cells causing type 1 diabetes
development requires pathogenic CD4 T-cell re-
sponses mediated by particular major histocompatibility
complex (MHC) class II molecules (1–3). However, studies
in NOD mice have led to a more recent appreciation that,
when expressed in the proper genetic context, some quite
common MHC class I variants can acquire an aberrant
ability to mediate autoreactive CD8 T-cell responses also
essential to diabetes development (4–9). Moreover, CD8
T-cells that recognize various pancreatic b-cell peptides in
the context of some particular MHC class I variants can
also be detected in the peripheral blood of human diabetic
patients (10–15). One relatively common MHC class I
variant that can contribute to diabetes susceptibility in
humans is HLA-A2.1 (16). Importantly, NOD.b2m
null.HHD
mice expressing human HLA-A2.1 but no murine MHC
class I molecules generate diabetes-inducing autoreactive
CD8 T-cell responses (17,18). NOD.b2m
null.HHD mice
have been found to generate HLA-A2.1–restricted auto-
reactive CD8 T-cell responses against three peptides each
derived from the pancreatic b-cell proteins islet-speciﬁc
glucose-6-phosphatase catalytic subunit–related protein
(IGRP228–236, IGRP265–273, and IGRP337–345) and insulin
(INS1 L3–11, INS1 B5–14, and INS1/2 A2–10) (17,18). Signiﬁ-
cantly, the homologous human peptides for Ins1/2 A2–10,
Ins1 B5–15, IGRP228–236, and IGRP265–273 are also recog-
nized by NOD.b2m
null.HHD CD8 T-cells (17,18). At least,
the IGRP228–236 and IGRP265–273 epitopes have also been
found to be the targets of HLA-A2.1–restricted CD8 T-cells
in human diabetic patients (10,19,20). For these reasons,
NOD.b2m
null.HHD mice would appear to represent an
ideal model for developing potentially clinically translat-
able interventions for suppressing diabetogenic HLA-A2.1–
restricted T-cell responses.
By avoiding the potential complications of generalized
immunosuppression, antigen-speciﬁc tolerance induction
therapies may ultimately represent a desirable diabetes
intervention approach in humans (21). Early support for
such a possibility was provided in an article by Amrani
et al. (22) that a free peptide injection approach, which
deleted high-avidity IGRP-reactive CD8 T-cells, blocked
progression to overt diabetes in standard NOD mice. Han
et al. (23) subsequently found that diabetes development
was more readily inhibited in NOD mice by a soluble IGRP
analog peptide treatment protocol that only depleted CD8
T-cells with high T-cell receptor avidity for this antigen
rather than one eliminating all such effectors. Even though
these soluble peptide treatments are effective, they are
particularly dependent on time of injection and antigenic
doses. An alternative antigen-speciﬁc method to induce
T-cell tolerance is intravenous treatment with syngeneic
splenocytes bearing ethylene carbodiimide (ECDI) cross-
linked peptides (peptide-SPs) or whole proteins. Treatment
with peptide-SPs that induce antigen-speciﬁc tolerance
has been reported to inhibit experimental autoimmune
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ORIGINAL ARTICLEencephalomyelitis in mice (24,25). Syngeneic spleen cells
bearing whole insulin as an ECDI-coupled autoantigen
have also been reported to exert a diabetes-protective ef-
fect in standard NOD mice (26). A peptide-SP approach has
also been shown to attenuate the activity of diabetogenic
BDC2.5 clonotypic CD4 T-cells in NOD mice (26). How-
ever, there have been no evaluations of whether a peptide-
SP approach could attenuate the activity of diabetogenic
CD8 T-cells, particularly those recognizing HLA-A2.1–
restricted antigenic epitopes that may be of potential high
clinical relevance in humans. We addressed this question
in the current study by determining whether syngeneic
splenocytes bearing any ECDI-coupled combination of
the HLA-2.1–restricted Ins1/2 A2–10, Ins1 B5–15, IGRP228–236,
and IGRP265–273 epitopes could suppress diabetes de-
velopment in NOD.b2m
null.HHD mice by modulating
pathogenic CD8 T-cell responses.
RESEARCH DESIGN AND METHODS
Mice. Previously described NOD.b2m
null.HHD mice (17) are maintained
by sibling matings at The Jackson Laboratory. MHC class I–deﬁcient
NOD.b2m
null mice have also been previously described (4). Some experi-
ments used an N10 backcross generation NOD stock congenically expressing
the CD45.2 rather than the CD45.1 variant leukocyte marker. NOD.b2m
null.
HHD mice in which antigen-presenting cells (APCs) speciﬁcally express an
MHC class II promoter (H2-Ea
k)–driven mouse proinsulin 2 transgene
(NOD.b2m
null.HHD-PI) were generated by crossing NOD.b2m
null.HHD with
previously described NOD.PI mice (27). The proinsulin transgene is main-
tained in a heterozygous state. The institutional Animal Care and Use Com-
mittee at The Jackson Laboratory approved all animal experiments.
Peptides and antibodies. Synthetic peptides Ins1/2 A2–10 (IVDQCCTSI), Ins1
B5–15 (HLCGPHLVEA), IGRP228–236 (FGIDLLWSV), IGRP265–273 (VLFGLGFAI),
and Flu16 (Flu MP58–66) (GILGFVFTL) were purchased from Mimotopes PTY,
Melbourne, Australia. Monoclonal antibodies speciﬁc for CD11c (clone N418),
CD8 (clone 53–6.72), CD45.1 (clone A201.7), and CD45.2 (clone 1042.1) were
purchased from BD Biosciences, San Jose, CA and eBiosciences, San Diego,
CA.
ECDI peptide-coupled cell treatment. ECDI peptide-coupled splenocyte
(peptide-SPs) treatment was carried out as previously described (28). Brieﬂy,
spleens were removed from syngeneic female mice, collagenase D treated
(Roche Diagnostics, Manheim, Germany), and the erythrocytes lysed. The
splenocytes were incubated with ECDI (150 mg/3.2 3 10
8 cells [Calbiochem,
La Jolla, CA]), and as indicated, a mixture of INS and/or IGRP peptide(s)
(1 mg/mL each) on ice for 1 h, hand-shaking every 10 min. The peptide-SPs
were washed, centrifuged, ﬁltered to remove cell clumps, and resuspended in
PBS. NOD.b2m
null.HHD female mice (4–6 weeks old) received 50 3 10
6
peptide-SPs in 200 mL PBS by intravenous injection. Controls consisted of
NOD.b2m
null.HHD female mice treated with splenocytes bearing the ECDI-
coupled HLA-A2.1 binding but diabetes-irrelevant Flu16 peptide. Multiple
treatments at 5-week intervals were given as indicated. The mice were mon-
itored for diabetes development.
Assessment of diabetes and insulitis development. Diabetes onset was
deﬁned by a urinary glucose value of $3 as assessed with Ames Diastix (Bayer,
Diagnostics Division, Elkhart, NJ). Mice were considered diabetic after two
consecutive positive measurements. Mice remaining free of overt diabetes
through 26 weeks posttreatment were killed and their pancreata ﬁxed in
Bouin’s solution and sectioned at three nonoverlapping levels. Granulated
b-cells were stained with aldehyde fuchsin and a hematoxylin and eosin
counterstain. Islets (at least 20 per mouse) were individually scored as fol-
lows: 0, no lesions; 1, peri-insular leukocytic aggregates, usually periductal
inﬁltrates; 2, ,25% islet destruction; 3, .25% islet destruction; and 4, complete
islet destruction. An insulitis score for each mouse was obtained by dividing
the total score for each pancreas by the number of islets examined. Overtly
diabetic mice were assigned an insulitis score of 4.
Enzyme-linked immunospot assays, CD8 T-cell culture, and in vivo
T-cell priming. Interferon (IFN)-g enzyme-linked immunospot (ELISPOT)
assays were performed as previously described (17). Spots were counted us-
ing an automated ELISPOT reader system (Immunospot; CTL Analyzers,
Cleveland, OH). An interluekin (IL)-10 ELISPOT assay was also used as in-
dicated. Numbers of IFN-g or IL-10 spots were normalized to the indicated
numbers of CD8 T-cells. NOD.b2m
null.HHD mice treated every 5 weeks with
peptide-SPs were primed in a rear footpad 2 days after the third treatment with
a cocktail containing 20 mg each of the HLA-A2.1–restricted Ins1/2 A2–10,I n s 1
B5–15, IGRP228–236, and IGRP265–273 peptides emulsiﬁed in 50 mL of complete
Freund’s adjuvant. Ten days after priming, the mice were killed, the popliteal
lymph nodes were isolated and dispersed by collagenase D treatment, and
CD8 T-cell reactions to each individual peptide were determined by IFN-g
ELISPOT analyses. Only mice remaining nondiabetic within each treatment
group were analyzed.
In vitro assessment of peptide-SP effects on diabetogenic CD8 T-cells.
Splenic CD8 T-cells were enriched from NOD.b2m
null.HHD mice by the pre-
viously described magnetic bead–based negative selection approach (29) and
incubated in vitro at a concentration of 5 3 10
5/mL with 5 3 10
6/mL INS- and/or
IGRP-SPs. The next day, the CD8 T-cells were recovered and assessed by IFN-g
ELISPOT analyses for reactivity against HLA-A2.1–restricted INS and IGRP
peptides. Irradiated (2000R) syngeneic NOD.b2m
null.HHD splenocytes were
used as APCs.
Soluble peptide treatment. Starting at 3 weeks of age, NOD.b2m
null .HHD
mice were treated with repeated intraperitoneal injections of a soluble mix-
ture containing 25 mg of each peptide (Ins A2–10,I n sB 5–15, IGRP228–236, and
IGRP265–273). Controls consisted of NOD.b2m
null.HHD female mice treated
with the Flu16 peptide. Three injections at 2-week intervals were followed by
treatments once every 3 weeks. The mice were monitored for type 1 diabetes
development.
Statistical analyses. Data were evaluated using Prism 5 software (GraphPad
Software). The log-rank test was used to compare diabetes incidence curves
and the nonparametric unpaired test to compare antigen-reactive CD8 T-cell
numbers between different treatment groups.
RESULTS
Splenocytes bearing ECDI-coupled peptides ablate
IGRP-speciﬁc CD8 T-cell responses in vitro. CD8
T-cells were enriched from pooled spleens of 9- to 16-week-
old NOD.b2m
null.HHD mice and cocultured in vitro with
syngeneic splenocytes bearing an ECDI-coupled cock-
tail of the HLA-A2.1–restricted Ins1/2 A2–10, Ins1 B5–15,
IGRP228–236, and IGRP265–273 b-cell autoantigens (INS/
IGRP-SPs) and assessed the next day for responsiveness to
each individual epitope by IFN-g ELISPOT analyses.
Compared with those exposed to the control Flu16 peptide
(Flu-SPs), CD8 T-cells from NOD.b2m
null.HHD mice
cocultured with INS/IGRP-SPs displayed signiﬁcantly de-
creased responses to restimulation by IGRP epitopes (Fig.
1A). Levels of reactivity to the HLA-A2.1–restricted INS
peptides was low among control CD8 T-cells exposed to
Flu16 and not further inﬂuenced by previous coculture
with INS/IGRP-SPs (Fig. 1A). Coincubation with syngeneic
splenocytes bearing an ECDI cross-linked mixture of the
two INS peptides (INS-SPs) did not diminish CD8 T-cell
responsiveness to INS or IGRP epitopes (Fig. 1B). How-
ever, preincubation with IGRP-SPs did signiﬁcantly di-
minish the ability of CD8 T-cells from NOD.b2m
null.HHD
mice to respond to restimulation by IGRP but not INS
epitopes (Fig. 1B). IL-10 ELISPOT analyses also indicated
that regardless of preincubation conditions, no CD8 T-cells
from NOD.b2m
null.HHD mice responding to INS or IGRP
stimulation produced this immunosuppressive cytokine.
On the basis of these collective data, we subsequently
assessed syngeneic INS/IGRP-SPs as a possible diabetes
intervention approach in NOD.b2m
null.HHD mice.
Syngeneic splenocytes bearing ECDI-coupled
autoantigenic IGRP, but not INS peptides, inhibit
diabetes development in NOD.b2m
null.HHD mice. Ini-
tial analyses found that repeated injections of a soluble
mixture of the four INS and IGRP peptides (25 mge a c h )d i d
not inhibit diabetes development in NOD.b2m
null .HHD
mice (data not shown). Thus, given the in vitro results
shown in Fig. 1, we assessed whether a single intravenous
injection of INS/IGRP-SPs given at 4–6 weeks of age could
protect NOD.b2m
null.HHD female mice from diabetes de-
velopment. Diabetes development was inhibited in mice
treated with the INS/IGRP-SPs, compared with controls
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tide(s) were responsible for the diabetes protective effects.
NOD.b2m
null.HHD mice were injected with syngeneic
splenocytes separately bearing either a mixture of the two
ECDI cross-linked INS (INS-SPs) or IGRP (IGRP-SPs) pep-
tides. Because one injection of INS/IGRP-SPs initially
afforded a partial diabetes protective effect, treatments with
INS-SPs and IGRP-SPs were repeated at 5-week intervals.
Compared with controls receiving Flu-SPs, only IGRP-SPs
and not INS-SPs exerted a diabetes protective effect in
NOD.b2m
null.HHD mice (Fig. 3). Treatments with syngeneic
splenocytes separately bearing either the ECDI-coupled
IGRP228–236 or IGRP265–273 peptide failed to signiﬁcantly
inhibit diabetes development in NOD.b2m
null.HHD mice
(Fig. 3A). Thus, splenocytes must bear a combination of
the ECDI-coupled IGRP228–236 and IGRP265–273 peptides
in order to elicit robust diabetes protective effects in
NOD.b2m
null.HHD mice. Furthermore, although both INS/
IGRP-SPs and IGRP-SPs treatment could inhibit overt di-
abetes development in NOD.b2m
null.HHD mice, neither in-
tervention signiﬁcantly suppressed insulitis levels (Fig. 3B).
INS/IGRP-SPs and IGRP-SPs inhibit in vivo responses
of HLA-A2.1–restricted IGRP but not INS autoreactive
CD8 T-cells in NOD.b2m
null.HHD mice. We assessed
whether the diabetes protective effect of INS/IGRP-SPs
treatment was associated with altered in vivo respon-
siveness of either HLA-A2.1–restricted INS or IGRP auto-
reactive CD8 T-cells in NOD.b2m
null.HHD mice. Two days
following a third INS/IGRP-SPs or Flu-SPs treatment given
at 5-week intervals, NOD.b2m
null.HHD mice were primed
in the footpad with a cocktail of the four INS and IGRP
peptides. Ten days postpriming, the mice were killed and
CD8 T-cells within the draining popliteal lymph nodes were
assessed for reactivity to each individual peptide by IFN-g
ELISPOT analyses. All mice were still nondiabetic at the
time of analysis. In INS/IGRP-SPs–treated NOD.b2m
null.
HHD mice, CD8 T-cell responses to both the HLA-A2.1–
restricted IGRP228–236 and IGRP265–273 peptides but neither
INS epitope were signiﬁcantly decreased (P = 0.03 and 0.004)
(Fig. 4). Treatment with IGRP-SPs but not with INS-SPs also
FIG. 1. HLA-A2.1–restricted b-cell antigenic peptides that are ECDI cross-linked to syngeneic splenocytes signiﬁcantly diminish responsiveness by
cognate CD8 T-cells from NOD.b2m
null.HHD mice. A: CD8 T-cells from NOD.b2m
null.HHD mice were incubated with syngeneic Flu-SPs or INS/
IGRP-SPs (bearing the complete mixture of IGRP265–273, IGRP228–236, INS1/2 A2–10, and INS1 B5–14 peptides). The next day, recovered CD8 T-cells
were cocultured for 48 h with 1 mmol/L of each of the individual INS or IGRP peptides, and antigen reactivity was assessed by ELISPOT analyses of
IFN-g production. B: CD8 T-cells from NOD.b2m
null.HHD mice were incubated with syngeneic Flu-SPs, IGRP-SPs (mixture of IGRP265–273 and
IGRP228–236), or INS-SPs (mixture of INS1/2 A2–10 and INS1 B5–14). T-cell reactivity to individual IGRP or INS peptides was then determined as
described above. All samples were evaluated in triplicate. Bars represent mean numbers of IFN-g spots 6 SEM. P values are based on comparison
with Flu-SPs. *P < 0.01, **P < 0.05; P values INS-SPs compared with IGRP-SPs, ***P < 0.01, ##P < 0.001.
FIG. 2. INS/IGRP-SPs inhibit diabetes development in NOD.b2m
null.
HHD mice. NOD.b2m
null.HHD female mice were injected intravenously
at 4–6 weeks of age with INS/IGRP-SPs (bearing the ECDI-linked mix-
ture of IGRP265–273, IGRP228–236, INS1/2 A2–10, and INS1 B5–14 peptides).
Controls were injected with syngeneic Flu-SPs. Mice were monitored
for diabetes development.
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both the IGRP228–236 and IGRP265–273 peptides (P =0 . 0 5a n d
0.002) (Fig. 4). These results further indicate that in the
context of the human HLA-A2.1 class I variant, autoreactive
CD8 T-cells recognizing the IGRP228–236 and/or IGRP265–273
peptides are of signiﬁcant pathogenic importance during
diabetes development in NOD.b2m
null.HHD mice.
Proinsulin is a pathogenic autoantigen in NOD.b2m
null.
HHD mice. Previous studies have indicated that (pro)insulin
is a key autoantigen for diabetes development in standard
NOD mice (27,30–33). This was partly demonstrated by
studies showing that MHC class II promoter–driven trans-
genic expression of proinsulin-2 in APCs of NOD mice
inhibits insulitis and diabetes development (27,30). Hence,
we used such a transgenic approach as an alternative means
to test whether (pro)insulin may also be an autoantigen
of pathogenic importance in NOD.b2m
null.HHD mice.
NOD.b2m
null.HHD mice expressing the previously described
(27) proinsulin-2 transgene in APCs (designated NOD.
b2m
null.HHD-PI) were generated and assessed for diabetes
development. As shown in Fig. 5A, compared with non-
transgenic controls, the rate of type 1 diabetes development
was somewhat retarded in NOD.b2m
null.HHD-PI female
mice but did not quite achieve statistical signiﬁcance (P =
0.08) by Kaplan-Meier analyses. However, as assessed by x
2
analyses, the cumulative frequency of diabetes development
by 35 weeks of age was signiﬁcantly lower (P , 0.005) in
NOD.b2m
null.HHD-PI mice than in nontransgenic controls.
Insulitis levels were also signiﬁcantly lower in NOD.b2m
null.
HHD-PI mice than in nontransgenic controls (Fig. 5B).
Baseline and primed levels of CD8 T-cell responses to the
HLA-A2.1–restricted Ins1/2 A2–10 or Ins1 B5–14 epitopes were
found not to differ in NOD.b2m
null.HHD-PI mice and non-
transgenic controls (data not shown). These ﬁndings do not
FIG. 3. Syngeneic splenocytes bearing a mixture of ECDI-coupled IGRP,
but not INS peptides, inhibit diabetes but not insulitis development in
NOD.b2m
null.HHD mice. Beginning at 4–6 weeks of age, NOD.b2m
null.
HHD female mice were injected intravenously at 5-week intervals with
either IGRP-SPs, INS-SPs, IGRP265–273-SPs, or IGRP228–236-SPs. Con-
trols were injected with Flu-SPs. A: Mice were monitored for diabetes
development. Only mice receiving IGRP-SPs developed diabetes at
a signiﬁcantly lower rate (P = 0.04) than Flu-SPs–treated controls.
B: Percentage of NOD.b2m
null.HHD mice in each treatment group with
the indicated range of insulitis scores.
FIG. 4. INS/IGRP-SPs and IGRP-SPs inhibit in vivo responses of HLA-
A2.1–restricted IGRP but not INS autoreactive CD8 T-cells. Beginning
at 4–6 weeks of age, NOD.b2m
null.HHD female mice were injected
intravenously with INS/IGRP-SPs, IGRP-SPs, INS-SPs, or Flu-SPs at
5-week intervals. Two days after the third treatment, mice were foot-
pad primed with a mixture of the four INS/IGRP peptides. Ten days
after priming, CD8 T-cells within the draining popliteal lymph nodes
were cocultured for 48 h with 1 mmol/L of each of the individual INS
or IGRP peptides. Antigen reactivity was assessed by ELISPOT analy-
ses of IFN-g production. All mice remained nondiabetic at the time of
analysis.
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topes, HLA-A2.1–restricted insulin autoreactive CD8 T-cells
are also important pathogenic contributors to diabetes de-
velopment in NOD.b2m
null.HHD mice. However, these APC
transgenic expression studies indicate that even if they do
not represent autoantigens recognized by pathogenic HLA-
A2.1–restricted CD8 T-cells, (pro)insulin derived epitopes are
important targets of at least diabetogenic CD4 T-cells in
NOD.b2m
null.HHD mice.
INS/IGRP-SPs do not have to share host MHC class I
identity to tolerize IGRP-speciﬁc CD8 T-cells and to
attenuate diabetes development in NOD.b2m
null.
HHD mice. It has been previously reported that spleno-
cytes bearing ECDI-coupled proteins or peptides do not
directly induce tolerogenic responses by CD4 T-cells in an
efﬁcient manner, but rather do so indirectly following their
uptake and processing by host-type APC (21). If this is also
the case for inducing CD8 T-cell tolerance, we reasoned it
should remain possible to inhibit diabetes development in
the HLA-A2.1–expressing NOD.b2m
null.HHD stock by
treatments with splenocytes from totally MHC class I–
deﬁcient NOD.b2m
null mice bearing the complete cocktail
of ECDI cross-linked INS and IGRP epitopes (designated
INS/IGRP-b2m
null SPs). Unlike those receiving Flu-b2m
null
FIG. 5. Insulitis and diabetes development in NOD.b2m
null.HHD-PI
mice. A: Incidence curve of diabetes development in NOD.b2m
null.HHD-
PI female mice and nontransgenic littermates. The rate of diabetes
development did not quite achieve a statistical difference (P = 0.08) by
Kaplan-Meier analyses. The cumulative frequency of diabetes de-
velopment by 35 weeks of age was signiﬁcantly different (P < 0.005) as
assessed by x
2 analyses. B: Histological grading of insulitis in pancreas
sections of 35-week-old female mice (NOD.b2m
null.HHD-PI mice, n =
14; NOD.b2m
null.HHD mice, n = 16).
FIG. 6. INS/IGRP-SPs do not have to share host-type MHC class I
identity to attenuate diabetes development in NOD.b2m
null.HHD mice.
Beginning at 4–6 weeks of age NOD.b2m
null.HHD mice were injected
intravenously at 5-week intervals with INS/IGRP-b2m
null SPs or Flu-
b2m
null SPs. A: Mice were monitored for diabetes development. B: INS/
IGRP-b2m
null SPs inhibit in vivo responses of HLA-A2.1–restricted
IGRP but not INS autoreactive CD8 T-cells in NOD.b2m
null.HHD mice.
Two days after the third treatment, mice were footpad primed with
a mixture of the four INS/IGRP peptides. Ten days after priming, CD8
T-cells within the draining popliteal lymph nodes of nondiabetic mice
were cocultured for 48 h with 1 mmol/L of each of the individual INS or
IGRP peptides, and antigen reactivity was assessed by ELISPOT anal-
yses of IFN-g production.
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INS/IGRP-b2m
null SPs-treated NOD.b2m
null.HHD mice
(Fig. 6A).
Two days after a third INS/IGRP-b2m
null SPs or
Flu-b2m
null SPs treatment given at 5-week intervals,
NOD.b2m
null.HHD mice were primed in the footpad with
a cocktail of the four INS and IGRP peptides. Ten days
postpriming, CD8 T-cells within the draining popliteal
lymph nodes were assessed for reactivity to each in-
dividual peptide by IFN-g ELISPOT analyses. CD8 T-cell
responses to both the HLA-A2.1–restricted IGRP228–236 and
IGRP265–273 peptides but again not the INS epitopes were
signiﬁcantly decreased in INS/IGRP-b2m
null SPs-treated
NOD.b2m
null.HHD mice (Fig. 6B). These collective results
indicate that in order to induce CD8 T-cell tolerance and to
elicit diabetes protective effects in NOD.b2m
null.HHD
recipients, donor cells bearing ECDI cross-linked HLA-
A2.1 restricted IGRP autoantigenic peptides do not also
have to express the relevant host-type MHC class I variant.
The results described above also indicated that rather
than directing inducing tolerogenic responses inhibiting
diabetogenic CD8 cell activity in NOD.b2m
null.HHD mice,
INS/IGRP-SPS or IGRP-SPs instead do so in an indirect
manner dependent on their uptake by host-type APC. To
directly test this possibility, we compared the ability of
ECDI-treated or untreated donor cells that were also
FIG. 7. More efﬁcient uptake by host-type splenic CD8+ DCs of ECDI-treated than untreated donor cells. Splenocytes from NOD.CD45.2 congenic
mice were labeled with the CFSE tracker dye and then subsequently treated or not with ECDI before being infused intravenously into standard
NOD CD45.1-expressing recipients. The following day, viable host-type splenic DCs were assessed by ﬂow cytometry for comparative uptake of
CFSE-labeled ECDI-treated or untreated donor cells. A: Depiction of gating strategy to assess uptake by viable (propidium iodide negative) host-
type CD45.1-expressing splenic DC subsets of CFSE-labeled donor-type leukocytes that had or had not been treated with ECDI. B: Mean
proportions 6 SEM of host-type splenic CD8+ DCs that had taken up CFSE-labeled ECDI-treated or untreated donor-type leukocytes (n =3 /
group). Signiﬁcantly greater uptake of ECDI-treated than untreated donor cells.
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ester (CFSE) tracker dye to be taken up by host-type
antigen-presenting dendritic cells (DCs). Donor- and
recipient-type cells were also distinguished by respective
expression of the CD45.2 versus CD45.1 pan-leukocyte
marker variant. There was a signiﬁcantly greater uptake by
host-type splenic CD8+ DCs of ECDI-treated than un-
treated donor cells that had been intravenously infused 1
day earlier (Fig. 7A and B). ECDI ﬁxation induces apo-
ptotic death of treated cells (21). This likely explains why
fewer ECDI-treated than untreated donor cells could be
detected in the recipients, but with the apoptotic status of
the former also allowing them to be more efﬁciently
engulfed by host-type DCs. These results indicate the
ability of donor cells bearing ECDI-coupled IGRP peptides
to elicit diabetes protective effects likely entails their up-
take by host-type DCs that then display the autoantigenic
epitopes to CD8 T-cells in a tolerance-inducing manner.
DISCUSSION
Our results indicate that treatment with INS/IGRP-SPs
(bearing an ECDI cross-linked mixture of the Ins1/2 A2–10,
Ins1 B5–15,I G R P 228–236, and/or IGRP265–273 peptides) inhibits
diabetes development in “humanized” NOD.b2m
null.HHD
mice. We found IGRP-SPs to be more effective than INS-
SPs in inhibiting diabetes development in NOD.b2m
null.
HHD mice. Furthermore, the inhibition of diabetes de-
velopment in NOD.b2m
null.HHD mice by INS/IGRP-SPs
treatment was associated with an attenuation of IGRP
but not INS-speciﬁc autoreactive CD8 T-cell responses.
Treatment with IGRP228–236 or IGRP265–273 single peptide-
SPs did not signiﬁcantly inhibit diabetes development in
NOD.b2m
null.HHD mice. This indicated that CD8 T-cell
tolerance must be established to both the HLA-A2.1–
restricted IGRP228–236 and IGRP265–273 epitopes in order to
elicit diabetes-protective effects in NOD.b2m
null.HHD
mice.
In standard NOD mice, insulin appears to be an earlier
target than IGRP of CD4 and CD8 T-cells initiating diabetes
development (31–33). It is unclear why INS/IGRP-SPs or
INS-SPs treatment did not alter levels of HLA-A2.1–
restricted CD8 responses against the Ins1/2 A2–10 or Ins1
B5–14 epitopes in NOD.b2m
null.HHD mice. However,
NOD.b2m
null.HHD mice transgenically expressing pro-
insulin-2 in APCs were largely protected from insulitis
and diabetes development. These APC transgenic studies
also indicated that even if diabetes development in
NOD.b2m
null.HHD mice does not require HLA-A2.1–
restricted CD8 responses targeting (pro)insulin epitopes,
an important component of their disease susceptibility still
entails CD4 T-cell responses against this pancreatic b-cell
antigen.
It has been previously reported that although peptide-
SPs can directly induce CD4 T-cell tolerance induction
processes in an inefﬁcient manner, they do so more efﬁ-
ciently through an indirect mechanism involving their up-
take and processing by host-type APCs (25). Because of
these alternative mechanisms, MHC compatibility between
splenotype donor and host is not required in order to in-
duce CD4 T-cell tolerance to ECDI-coupled antigens, al-
though syngeneic donor cells are more efﬁcient at doing
so. We found INS/IGRP peptides ECDI coupled to com-
pletely MHC class I–deﬁcient donor splenocytes strongly
inhibited IGRP-speciﬁc CD8 T-cell responses and diabetes
development in NOD.b2m
null.HHD mice. Hence, donor/host
MHC class I compatibility is not required to efﬁciently in-
duce CD8 T-cell tolerance to ECDI-coupled self-antigenic
peptides. These ﬁndings indicate that IGRP-SPs inhibit
diabetes development in NOD.b2m
null.HHD mice by in-
ducing CD8 T-cell tolerance through an indirect host-type
APC-dependent pathway. Indeed, other data indicate that
host-type DCs more efﬁciently take up donor ECDI-treated
than untreated leukocytes.
A review by Luo et al. (21) discusses efforts by the Im-
mune Tolerance Network to develop a clinical trial using
ECDI insulin-coupled peripheral blood lymphocytes as
a possible diabetes intervention in humans. Our current
results indicate that the use of “humanized” NOD.b2m
null.
HHD mice and other related strains may facilitate the
development of clinically translatable peptide-based ther-
apies for diabetic patients. In particular, currently avail-
able “humanized” mouse resources make it possible to
determine which autoantigenic peptides when ECDI cross-
linked to autologous leukocytes are most likely to atten-
uate HLA-A2.1–restricted CD8 T-cell responses that recent
evidence (10–16) indicates may be important for diabetes
development in many human patients.
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